Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
6(75.0%)
Phase 2
2(25.0%)
8Total
Phase 1(6)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04464239Phase 1Completed

A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants

Role: lead

NCT03093025Phase 2Terminated

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

Role: lead

NCT03919409Phase 1Completed

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

Role: lead

NCT03746067Phase 1Completed

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

Role: lead

NCT03742791Phase 1Completed

Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers

Role: lead

NCT03141658Phase 1Completed

Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects

Role: lead

NCT02448212Phase 1Completed

Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects

Role: lead

NCT00914186Phase 2Completed

Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)

Role: lead

All 8 trials loaded